Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.

By F. Chan, S. Chung, B. Suen, Yuk-tong Lee, W. Leung, V. Leung, Justin C.Y. Wu, J. Lau, Y. Hui, M. Lai and 2 more. New England Journal of Medicine, 2001

704 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/517a7772017a4aafde7c8c41c86052b5879e47f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. E. Kuipers
2. J. Atherton

Citations in the corpus

• Pathogenesis of Helicobacter pylori Infection (2006, neutral): “of recurrent NSAID-associated ulcer bleeding (82).”
• Helicobacter pylori infection. (2009, background): “19% with 1-week triple eradication regimen (bismuth subcitrate 150 people taking naproxen with H pylori and a bleeding peptic ulcer that healed with [12]”
• Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report (2016, background): “45 46 54 A few clinical trials 49 55 56 and one observational study, 50 conducted in these high risk patients of Chinese origin, have shown that H. pylori eradication reduces but does not eliminate that risk, and that PPI co-therapy seems still necessary to reduce further the risk of upper GI…”